Cardiac drugs and outcome in COVID-19
| dc.contributor.author | Mishra, Ajay Kumar | |
| dc.contributor.author | Sahu, Kamal Kant | |
| dc.contributor.author | Sargent, Jennifer B. | |
| dc.date | 2022-08-11T08:08:09.000 | |
| dc.date.accessioned | 2022-08-23T15:44:26Z | |
| dc.date.available | 2022-08-23T15:44:26Z | |
| dc.date.issued | 2020-04-14 | |
| dc.date.submitted | 2020-04-15 | |
| dc.identifier.citation | <p>Mishra AK, Sahu KK, Sargent J. Cardiac drugs and outcome in COVID - 19. QJM. 2020 Apr 14:hcaa127. doi: 10.1093/qjmed/hcaa127. Epub ahead of print. PMID: 32289168. <a href="https://doi.org/10.1093/qjmed/hcaa127">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 1460-2393 (Linking) | |
| dc.identifier.doi | 10.1093/qjmed/hcaa127 | |
| dc.identifier.pmid | 32289168 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/27314 | |
| dc.description.abstract | We read with much interest the article “Are certain drugs associated with enhanced mortality in COVID -19” by Goldstein et al your esteemed Journal. Authors have discussed the theoretical basis of angiotensin receptor blockers, statins in worsening outcome of COVID – 19 patients.(1) We believe that this topic is rapidly evolving and requires further evidence and discussion for understanding the multiple factors which contribute to the pathogenesis and outcome. We have the following comments. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32289168&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | © The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians. Accepted manuscript posted after 12 months as allowed by publisher's self-archiving policy at https://academic.oup.com/journals/pages/self_archiving_policy_b | |
| dc.subject | cardiac drugs | |
| dc.subject | COVID-19 | |
| dc.subject | coronavirus | |
| dc.subject | mortality | |
| dc.subject | angiotensin receptor blockers | |
| dc.subject | pathogenesis | |
| dc.subject | letter to the editor | |
| dc.subject | Cardiology | |
| dc.subject | Cardiovascular Diseases | |
| dc.subject | Infectious Disease | |
| dc.subject | Virus Diseases | |
| dc.title | Cardiac drugs and outcome in COVID-19 | |
| dc.type | Accepted Manuscript | |
| dc.source.journaltitle | QJM : monthly journal of the Association of Physicians | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1009&context=covid19&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/covid19/10 | |
| dc.legacy.embargo | 2021-04-14T00:00:00-07:00 | |
| dc.identifier.contextkey | 17371008 | |
| refterms.dateFOA | 2022-08-23T15:44:26Z | |
| html.description.abstract | <p>We read with much interest the article “Are certain drugs associated with enhanced mortality in COVID -19” by Goldstein et al your esteemed Journal. Authors have discussed the theoretical basis of angiotensin receptor blockers, statins in worsening outcome of COVID – 19 patients.(1) We believe that this topic is rapidly evolving and requires further evidence and discussion for understanding the multiple factors which contribute to the pathogenesis and outcome. We have the following comments.</p> | |
| dc.identifier.submissionpath | covid19/10 | |
| dc.contributor.department | Department of Medicine, Division of Hospital Medicine |
